HR 1525 · in committee · significant
Protecting Life from Chemical Abortions Act
- reproductive rights
What this bill does
- This bill reverses FDA rule changes that allowed pharmacies to mail mifepristone (abortion pill) to patients.
- It affects patients seeking medication abortion, healthcare providers, and pharmacies that dispense mifepristone.
- The bill reinstates in-person dispensing requirements and blocks further FDA changes until states report abortion data.
Generated by claude-haiku-4-5
Community Threads
Started by Cosponsor
- 01
How would reinstating in-person dispensing requirements affect access to medication abortion for patients in rural or underserved areas?
- 02
What evidence exists that in-person dispensing of mifepristone improves safety outcomes compared to mail delivery?
- 03
How would blocking FDA regulatory changes until states report abortion data impact the FDA's ability to respond to new medical evidence?
Cosponsor writes these to seed civic discussion — they aren't user posts. Sign in to reply.
Sponsor · R-OK-1
Kevin Hern
Citizen cosponsors
0
In Congress
24/ 435
House Reps cosponsoring
Introduced 2025-02-24
Joining the bill
Robert B. Aderholt
R-AL-4 · original
Lauren Boebert
R-CO-4 · original
Mike Bost
R-IL-12 · original
John W. Rose
R-TN-6 · original
Keith Self
R-TX-3 · original
Daniel Webster
R-FL-11 · original
Randy K. Weber, Sr.
R-TX-14 · original
James R. Baird
R-IN-4 · original
Dan Crenshaw
R-TX-2 · original
Warren Davidson
R-OH-8 · original
Troy Downing
R-MT-2 · original
Randy Feenstra
R-IA-4 · original
+ 12 more
Legislative timeline
2025-02-24 · house · IntroReferral
Referred to the House Committee on Energy and Commerce.
2025-02-24 · IntroReferral
Introduced in House
2025-02-24 · IntroReferral
Introduced in House
Citizen comments
Sign in to comment on this bill.
No comments yet — be the first.